| Name | Title | Contact Details |
|---|
Aeras is constantly producing new constructs that will also be made available following phenotypic, genotypic and stability characterization. Aeras is also glad to provide shigella carrier strains with capsids expressing TB antigens under similar
RareMed Solutions offers comprehensive support services for specialty, orphan and ultra-orphan products. Our team has a breadth of experience developing and maintaining therapy specific solutions to ensure compliance. RareMed Solutions is the ideal partner for biotech firms and pharmaceutical manufacturers due to our custom solutions that are unique to each of our partner’s needs. RareMed Solutions is committed to providing the highest level of care to patients we serve. We offer specialized, highly-customizable services designed to increase patient access, affordability, and adherence to therapy. The extensive experience and unmatched service delivery translates to the best possible care for patients as well as enhancing product performance.
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company`s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries.
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
At Behavioral Health Professionals, Inc. we take pride in offering expert behavioral health management services. It’s all we do.